High5 Oncology TV: SABCS 2024

Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreiche

Read the full article here

Source: high5oncology.tv

Categories: Oncologists1, General Medicine News

Tags: SABCS24

Tweets with this article

OncoAlert

EMBER3 Presented at #SABCS24 and out on @NEJM Report with Peter Fasching ( @high5md ) https://t.co/e8KCGT3rdi Imlunestrant is a novel oral medication that targets and degrades estrogen receptors (ER), even in breast cancers resistant to traditional hormone therapies due to ER… https://t.co/Fhts3V34dQ https://t.co/np8nNlrxbo

Vagus nerve stimulation relieves severe depression | WashU Medicine

Results of major clinical trial may pave the way to health insurance coverage for treatment-resistant cases

Washington U. Med December 18, 2024

Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma

Oncogene – Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma

Oncogene Journal December 18, 2024

Role of GLP-1 agonists in breast cancer survivorship setting

Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential use of GLP-1 or GLP agonist and incretin mimetics during…

VJ Oncology December 18, 2024

The WHO’s 5th classification for AML: expanding the number of genetically defined categories

Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides insight into the 5th iteration of the World Health Organization’s (WHO)…

VJHemOnc December 18, 2024

Biomarkers and Treatment Strategies in CAR T-Cell Therapy for R/R Multiple Myeloma

Doris K. Hansen, MD, discussed a comprehensive analysis of pretreatment biomarkers associated with outcomes in patients receiving idecabtagene vicleucel therapy

Targeted Oncology December 18, 2024

The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has changed treatment landscape of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and more older patients have…

Chimeric Antigen Receptor T-Cell (CAR-T) December 18, 2024

Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis – Benedetta E Di Majo, Francesca Vendemini, Sonia Bonanomi, Pietro Casartelli, Sara Napolitano, Giorgio Ottaviano, Giulia Prunotto, Marta Verna, Alessandra Sala, Guglielmo M Migliorino, Frances

Introduction: The association of acute lymphoblastic leukaemia (ALL) and cystic fibrosis (CF) is rare. We present the case of a paediatric patient affected by C…

Chimeric Antigen Receptor T-Cell (CAR-T) December 18, 2024

Related Articles